Neural and motivational mechanisms of age-related change in emotion regulation: Administrative Supplement

与年龄相关的情绪调节变化的神经和动机机制：行政补充

• 批准号: 10654278
• 负责人: Tammy English
• 金额: $ 37.79万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-04-15 至 2026-01-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10654278
• 关键词: Address; Administrative Supplement; Adult; Affective; Age; Aging; Alzheimer associated neurodegeneration; Alzheimer' s Disease; Amyloid; Amyloid beta-Protein; Anatomy; Attenuated; Behavior assessment; Behavioral; Biological Markers; Blood; Brain; Cognitive; Collaborations; Communities; Corpus striatum structure; Data; Data Collection; Development; Dimensions; Ecological momentary assessment; Elderly; Emotional; Emotions; Ensure; Facial Expression; Foundations; Functional Magnetic Resonance Imaging; Funding; Glial Fibrillary Acidic Protein; Goals; Grant; Human Resources; Image; Individual; Individual Differences; Influentials; Intervention; Knowledge; Laboratories; Lateral; Life; Literature; Major Depressive Disorder; Mass Spectrum Analysis; Matched Group; Measures; Mental Depression; Mental Health; Mental disorders; Methods; Mission; Modeling; Motivation; Nerve Degeneration; Neurobiology; Nucleus Accumbens; Participant; Pathologic; Pathology; Pathway interactions; Pattern; Personal Satisfaction; Plasma; Play; Population; Prefrontal Cortex; Process; Protocols documentation; Quality of life; Recording of previous events; Recurrence; Research; Research Personnel; Research Project Grants; Rewards; Risk; Risk Factors; Role; Sampling; Self-control as a personality trait; Source; System; Testing; Thick; Universities; Update; Variant; Ventral Striatum; Washington; age related; base; blood-based biomarker; cognitive control; cognitive function; cost effective; design; emotion regulation; emotional experience; emotional functioning; experience; healthy aging; improved; individual variation; insight; magnetic resonance imaging biomarker; medical schools; middle age; neuroimaging; neuroimaging marker; neuromechanism; neuropathology; novel; pilot test; positive emotional state; pre-clinical; prevent; prospective; relating to nervous system; response; side effect; single molecule; success; tau Proteins; trait

Project Summary: In the progression from middle to older-age, healthy adults typically experience improvements in their emotional functioning, such as increases in positive emotion and greater expertise in managing emotions. However, not everyone shows these age-related improvements, and the mechanisms that give rise to emotional functioning changes across adulthood are still poorly understood. The primary goal of this project is to examine the critical factors that promote positive emotional development in normative aging, and to test whether depression history might moderate this process as a key trait individual difference marker. To this end, we test our proposed Value-Based Cognitive Control Model of Emotion Regulation in ADulthood (VBCC-MERiAD). The VBCC-MERiAD framework suggests a novel insight: that interactions between reward motivation and cognitive control play a central role in understanding both the normative trajectory of emotional functioning in older adults, and conversely, why and how individuals with depression histories may get “off track”. Our primary hypothesis is that emotion regulation (ER) abilities rely upon the integrity of fronto-striatal circuitry (i.e., activity and connectivity between the lateral prefrontal cortex and nucleus accumbens / ventral striatum), to successfully utilize reward motivation as a means of engaging cognitive control (i.e., to update and maintain ER goals). Across three Specific Aims, we will characterize the mechanisms of ER in middle-aged and older adults (N=220, ages 35-75) using a multi-method design involving functional neuroimaging measures, laboratory behavioral assessments, and experience sampling methods, to identify the neural and behavioral indicators of motivation and cognitive control that predict daily emotional functioning, and potential dysregulation in individuals with depression history. We further propose to enrich our understanding of the mechanisms of age-related change in ER, by capitalizing on recent advances in the ability to assess risk of preclinical Alzheimer’s Disease (AD) and AD-related neurodegeneration through the use of blood plasma-based biomarkers. Through new collaborations with Dr. Suzanne Schindler and Dr. Brian Gordon, our partners at both Washington University, Knight Alzheimer’s Disease Research Center, we will utilize state-of-the-art methods, including single-molecule array (Simoa) and mass spectrometry, to comprehensively assess key blood-based biomarkers related to amyloid (APOE, beta-amyloid), tau (ptau181), and neurodegeneration (NfL, GFAP), as well as anatomical MRI biomarkers (e.g., cortical thickness). We propose an Administrative Supplement to provide additional support for us to acquire, process and rigorously analyze AD- related biomarker data. This Supplement will dramatically enhance the scope and impact of our project, by enabling us to extend our understanding of both normative and dysfunctional age-related change in emotional function, by not only identifying mechanisms that promote positive ER in late adulthood, but also determining the degree to which otherwise undetected preclinical AD moderates such effects. In so doing, we will lay the foundation for new interventions to improve quality of life for older adults and individuals with depression history.

项目摘要：从中年到老年人的发展，健康的成年人通常会得到改善 在他们的情感功能中，例如积极情绪的增加和在管理情绪方面的专业知识。 但是，并非所有人都表现出这些与年龄相关的改进，以及引起情感的机制 整个成年期的功能变化仍然知之甚少。该项目的主要目标是检查 在正常衰老中促进积极情绪发展的关键因素，并测试抑郁症是否 历史可能会将此过程作为关键特征个体差异标记。为此，我们测试了我们的建议 成年中基于价值的认知控制模型（VBCC-梅里亚德）。 VBCC梅里亚德 框架提出了一种新颖的见解：奖励动机与认知控制之间的相互作用可以发挥 在了解老年人情绪功能的正常轨迹方面的核心作用，相反， 为什么以及如何以及如何“偏离轨道”。我们的主要假设是情感 调节（ER）能力依赖于额叶纹状体电路的完整性（即，活动和连通性 外侧前额叶皮层和伏隔核 /腹侧纹状体），成功利用奖励动机为 参与认知控制的手段（即更新和维护ER目标）。在三个具体目标中，我们将 使用多方法来表征中年和老年人中ER的机制（n = 220，年龄在35-75岁） 设计涉及功能性神经影像措施，实验室行为评估和经验抽样 方法，以确定预测每天的动机和认知控制的神经元和行为指标 情绪功能和抑郁史患者的潜在失调。我们进一步建议 通过利用最近的进步，使我们对ER年龄相关变化机制的理解充实 评估临床前阿尔茨海默氏病（AD）的风险和与广告相关的神经变性的能力 使用基于血浆的生物标志物。通过与Suzanne Schindler博士和Brian博士的新合作 戈登是华盛顿大学的合伙人，骑士阿尔茨海默氏病研究中心，我们将利用 最先进的方法，包括单分子阵列（SIMOA）和质谱法，以全面 评估与淀粉样蛋白（APOE，β-淀粉样蛋白），TAU（PTAU181）和 神经变性（NFL，GFAP）以及解剖学MRI生物标志物（例如皮质厚度）。我们提出了一个 行政补充，为我们提供额外的支持，以获取，处理和严格分析ad- 相关的生物标志物数据。这种补充剂将大大提高我们项目的范围和影响 使我们能够扩展对正常和功能失调与年龄相关的情感变化的理解 功能，不仅通过识别在成年后期促进正ER的机制，还可以确定 其他未发现的临床前AD的程度可以调节这种影响。这样做，我们将奠定基础 为了改善老年人和患有抑郁史的个人生活质量的新干预措施。